ライフサイエンスコーパス: pertuzumab

1 led ((124)I, (125)I) HER2-specific antibody (pertuzumab).

2 locked in cells pretreated with lapatinib or pertuzumab.

3 b alone and in combination with lapatinib or pertuzumab.

4 , including trastuzumab, trastuzumab-DM1 and pertuzumab.

5 e agents or a combination of trastuzumab and pertuzumab.

6 usceptibility to the HER2-targeted inhibitor pertuzumab.

7 y the therapeutic antibodies trastuzumab and pertuzumab.

8 eased in patients treated with gemcitabine + pertuzumab.

9 to 1.03; P = .07) in favor of gemcitabine + pertuzumab.

10 cancer were enrolled and administered (89)Zr-pertuzumab.

11 ent, when exposed to the anti-HER-2 antibody pertuzumab.

12 umab in a total antibody mass of 20-50 mg of pertuzumab.

13 docetaxel, carboplatin, and trastuzumab plus pertuzumab.

14 the anti-tumor efficacies of trastuzumab and pertuzumab.

15 evant benefit in patients who received prior pertuzumab.

16 ion that received both prior trastuzumab and pertuzumab.

17 eness analysis to assess the value of adding pertuzumab.

18 ost-effectiveness studies of trastuzumab and pertuzumab.

19 were recruited to a dose-escalation study of pertuzumab (0.5 to 15 mg/kg) given intravenously every 3

20 tients who were randomly assigned to receive pertuzumab (2400 patients) or placebo (2405 patients) ha

21 pertuzumab (trastuzumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses

22 ng dose --> 6 mg/kg) once every 3 weeks plus pertuzumab (840 mg loading dose --> 420 mg) once every 3

23 mg/m(2) from cycle 2 if tolerated; group A), pertuzumab (840 mg loading dose, followed by 420 mg ever

24 y assigned to also receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every

25 r MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequentl

26 Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a

27 rapeutic target, we examined the activity of pertuzumab, a HER2 antibody that inhibits HER3 signaling

28 Pertuzumab, a humanized antibody that prevents HER2 dime

29 Pertuzumab, a recombinant humanized monoclonal antibody

30 Incubation of EAC cells with trastuzumab and pertuzumab accelerated the expression of EMT markers, co

31 e designs were used to evaluate two doses of pertuzumab administered intravenously once every 3 weeks

32 or patients who crossed over from placebo to pertuzumab after the interim analysis.

33 bination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patient

34 Pertuzumab also potentiated the effects of MEK inhibitor

35 Pertuzumab, an anti-HER2 humanized monoclonal antibody t

36 Results: Twenty-one patients received pertuzumab and 19 completed at least two cycles.

37 ive-disease-free survival rate of 91.8% with pertuzumab and 89.2% with placebo.

38 of two humanized monoclonal antibodies (mAb) pertuzumab and bevacizumab.

39 B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D).

40 o investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HE

41 The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15

42 s) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and

43 activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we re

44 The combination of pertuzumab and trastuzumab resulted in a clinical benefi

45 therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than

46 study to evaluate the efficacy and safety of pertuzumab and trastuzumab with paclitaxel given once pe

47 the HER2 binding antibodies Trastuzumab and Pertuzumab and two EGFR binding antibodies including Cet

48 peptides based on the binding of HER-2 with pertuzumab and VEGF with VEGFR2.

49 Trastuzumab, pertuzumab, and taxane for first-line treatment and T-DM

50 s exposed to the combination of trastuzumab, pertuzumab, and the TGFbeta inhibitor expressed epitheli

51 n mice given the combination of trastuzumab, pertuzumab, and the TGFbeta inhibitor than in mice given

52 have gained regulatory approval: lapatinib, pertuzumab, and trastuzumab-emtansine.

53 ved six weekly treatments of trastuzumab and pertuzumab; and an ultrasound+antibody group that receiv

54 ti-ERBB1 Mab), trastuzumab (anti-ERBB2 Mab), pertuzumab (anti-ERBB2 Mab), and lapatinib (dual ERBB1 a

55 o HER2-expressing tumors when trastuzumab or pertuzumab are already employed.

56 nt benefit was observed in the gemcitabine + pertuzumab arm compared with the gemcitabine alone arm (

57 reported in one patient in the gemcitabine + pertuzumab arm.

58 ith disease progression continued to receive pertuzumab (at the same dose), with the addition of tras

59 positive disease, confirming that the (89)Zr-pertuzumab avidity was a true-positive result for HER2-p

60 months with a combination of trastuzumab and pertuzumab became resistant to chemotherapeutic agents (

61 MBC who received T-DM1 after trastuzumab and pertuzumab between March 1, 2013, and July 15, 2015, via

62 stant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib (TPB

63 AC cells become resistant to trastuzumab and pertuzumab by activating TGFbeta signaling, which induce

64 T-DM1 and pertuzumab can be combined at full doses with no unexpec

65 Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic

66 for their metastatic disease to receive the pertuzumab combination or the placebo combination.

67 3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95

68 ling and cell proliferation than trastuzumab/pertuzumab combinations with similar activity in vivo.

69 13.8% in patients who received gemcitabine + pertuzumab compared with 4.6% in patients who received g

70 uggested prolonged median survival time with pertuzumab compared with historical controls.

71 on of the crystal structure of the HER-2/neu-pertuzumab complex demonstrated that the receptor dimeri

72 Patients received a loading dose of 840 mg pertuzumab (cycle 1) followed by 420 mg for subsequent c

73 Neither alpha-IR3 nor pertuzumab decreased HER-2 phosphorylation, suggesting t

74 [<1%] of 223 with trastuzumab emtansine plus pertuzumab), diarrhoea (33 [15%] vs 2 [<1%]), and febril

75 The treatment effect of pertuzumab did not differ significantly by stromal TIL v

76 docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under

77 Patients received pertuzumab every 3 weeks.

78 Tumors exposed to trastuzumab and pertuzumab expressed EMT markers and were poorly differe

79 Pertuzumab extended the median duration of response by 7

80 docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (three [1%] vs seven [3%]), alanine

81 docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer patients receiving trastuzumab emtansi

82 docetaxel, carboplatin, and trastuzumab plus pertuzumab group (absolute difference -11.3 percentage p

83 had not been reached (95% CI 42.4-NE) in the pertuzumab group (hazard ratio 0.66, 95% CI 0.52-0.84; p

84 ebo group and 18.7 months (16.6-21.6) in the pertuzumab group (hazard ratio 0.69, 95% CI 0.58-0.81).

85 l group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death,

86 investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.

87 3 patients in the trastuzumab emtansine plus pertuzumab group and 123 (55.7%) of 221 patients in the

88 rence occurred in 171 patients (7.1%) in the pertuzumab group and 210 patients (8.7%) in the placebo

89 sive-disease-free survival were 94.1% in the pertuzumab group and 93.2% in the placebo group.

90 asive-disease-free survival was 97.5% in the pertuzumab group and 98.4% in the placebo group (hazard

91 alysis was not adjusted for crossover to the pertuzumab group and is therefore conservative.

92 im analysis of overall survival favoured the pertuzumab group but was not significant.

93 rrhea of grade 3 or above were higher in the pertuzumab group than in the control group.

94 nger median progression-free survival in the pertuzumab group than in the placebo group.

95 rse events in the trastuzumab emtansine plus pertuzumab group were decreased platelet count (three [1

96 docetaxel, carboplatin, and trastuzumab plus pertuzumab group were neutropenia (55 [25%] of 219 vs on

97 pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time

98 acebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001),

99 asive-disease-free survival was 92.0% in the pertuzumab group, as compared with 90.2% in the placebo

100 he placebo group and 113 (28%) of 402 in the pertuzumab group.

101 red in the chemotherapy plus trastuzumab and pertuzumab group.

102 atients receiving trastuzumab emtansine plus pertuzumab had a grade 3-4 adverse event (29 [13%] of 22

103 Pertuzumab has no clinically significant single-agent ac

104 Although pertuzumab has some activity in patients with HER2-posit

105 argeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and ser

106 f not previously administered) and may offer pertuzumab, if the patient has not previously received i

107 ients underwent PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-50 mg of pertu

108 all survival was significantly improved with pertuzumab in an interim analysis without the median bei

109 eeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory

110 sess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC

111 antibody group that received trastuzumab and pertuzumab in combination with six weekly sessions of BB

112 PFS benefits for docetaxel, trastuzumab, and pertuzumab in first-line treatment, and the EMILIA trial

113 xel cohorts, meriting further exploration of pertuzumab in ovarian cancer.

114 group analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, me

115 f biomarkers that would predict benefit from pertuzumab in this setting.

116 etaxel plus trastuzumab (TH) with or without pertuzumab in US patients with metastatic breast cancer.

117 ed agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic br

118 Pertuzumab increases the rate of pathological complete r

119 Pertuzumab inhibited ligand-dependent morphogenesis in t

120 Pertuzumab injection was followed 8 h later by the deliv

121 and PET were performed at 24 and 48 h after pertuzumab injection.

122 Pertuzumab is a humanized monoclonal antibody that inhib

123 plete response) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab

124 xel given once per week with trastuzumab and pertuzumab is highly active and well tolerated and seems

125 Pertuzumab is well tolerated with a RR of 4.3% in heavil

126 These results demonstrate that pertuzumab is well tolerated, has a pharmacokinetic prof

127 nation with anti-EGFR (RG7160) or anti-HER2 (pertuzumab) mAbs.

128 Pertuzumab may add activity to gemcitabine for the treat

129 In addition, pertuzumab-mediated inhibition of ErbB2 heterodimerizati

130 val was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively).

131 All 29 patients enrolled for pertuzumab monotherapy experienced disease progression.

132 BR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy.

133 umab to patients whose disease progressed on pertuzumab monotherapy.

134 docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221).

135 nt treatment with trastuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastu

136 me regimen with a matching placebo replacing pertuzumab (n=406).

137 Pertuzumab (Omnitarg) is a humanized mAb directed agains

138 Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized mon

139 2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting

140 to receive either trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab pl

141 ve, operable breast cancer to receive either pertuzumab or placebo added to standard adjuvant chemoth

142 2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and doc

143 ase 3 study comparing the addition of either pertuzumab or placebo to first-line therapy with trastuz

144 cer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significant

145 cer treated with docetaxel, trastuzumab, and pertuzumab or placebo, higher TIL values are significant

146 onoclonal antibodies such as trastuzumab and pertuzumab, or small scaffold proteins such as affibody

147 evaluated the safety and dosimetry of (89)Zr-pertuzumab PET/CT for human epidermal growth factor rece

148 breast cancers and brain metastases, (89)Zr-pertuzumab PET/CT suggested that the brain metastases we

149 successful HER2-targeted imaging with (89)Zr-pertuzumab PET/CT.

150 to 1.11; P = .14; median PFS, 4.3 months for pertuzumab plus chemotherapy v 2.6 months for placebo pl

151 rastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab g

152 The combination of pertuzumab plus trastuzumab plus docetaxel, as compared

153 l survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel.

154 2-targeting antibodies (i.e. trastuzumab and pertuzumab) prolong survival in HER2-positive breast can

155 Pertuzumab represents a new class of targeted anticancer

156 Pertuzumab represents a new class of targeted therapeuti

157 The addition of pertuzumab resulted in an additional 1.81 life-years gai

158 docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achi

159 oading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in the other group]).

160 Pertuzumab significantly improved the rates of invasive-

161 ATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free

162 and the addition of the second HER2 antibody pertuzumab substantially increases the magnitude of this

163 ring chemotherapy and was more frequent with pertuzumab than with placebo (9.8% vs. 3.7%).

164 Diarrhea was more common with pertuzumab than with placebo.

165 ia in Solid Tumors after 1.5 and 6 months of pertuzumab therapy, and lasted for 11 and 10 months, res

166 Adding pertuzumab to chemotherapy did not significantly improve

167 ed phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-res

168 -month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-l

169 ve metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared wit

170 d breast cancer and also suggest that adding pertuzumab to trastuzumab may augment therapeutic benefi

171 s) of neoadjuvant trastuzumab emtansine plus pertuzumab (trastuzumab emtansine 3.6 mg/kg; pertuzumab

172 ase were randomly assigned to receive either pertuzumab, trastuzumab, and docetaxel (n=402) or the sa

173 ificant improvement in overall survival with pertuzumab, trastuzumab, and docetaxel in patients with

174 NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a signific

175 study to compare the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, tra

176 docetaxel and 148 (36%) of 408 who received pertuzumab, trastuzumab, and docetaxel, and included feb

177 antly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with

178 m suggested that survival was prolonged with pertuzumab treatment, compared with historic controls wi

179 al, clinicopathological characteristics, and pertuzumab treatment.

180 s showed a slightly increased sensitivity to pertuzumab versus parental cells.

181 (89)Zr-pertuzumab was able to image multiple sites of malignanc

182 ree survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel.

183 Pertuzumab was conjugated with deferoxamine and radiolab

184 d a NHB of 13.8 QALMs versus strategy C when pertuzumab was included in strategy C.

185 d a NHB of 13.8 QALMs versus strategy C when pertuzumab was included in strategy C.

186 The effect on PFS favoring pertuzumab was more pronounced in the gemcitabine and pa

187 validated the model using experiments where pertuzumab was used to block HER2 dimerization.

188 Pertuzumab was well tolerated and resulted in no objecti

189 Pertuzumab was well tolerated with diarrhea in 69.1% (11

190 Pertuzumab was well tolerated.

191 Pertuzumab was well tolerated.

192 Pertuzumab was well tolerated; diarrhea was the most com

193 Importantly, these activities of pertuzumab were distinct from those of trastuzumab, a mo

194 The pharmacokinetics of pertuzumab were similar to other humanized immunoglobuli

195 ation of two classes of drugs (cisplatin and pertuzumab) when delivered by these two alternative rout

196 In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemo

197 umab (an inhibitor of HER2), with or without pertuzumab (which inhibits dimerization of HER2 with HER

198 In contrast, the HER2 antibody pertuzumab, which blocks HER2 heterodimerization, inhibi

199 vity of T-DM1 in patients who received prior pertuzumab, which is now included as standard first-line

200 estimate progression-free survival (PFS) of pertuzumab with gemcitabine in patients with platinum-re

201 ited a third cohort of patients who received pertuzumab without trastuzumab.